Strides Arcolab Limited  

(Public, BOM:532531)   Watch this stock  
Find more results for 532531
885.10
+5.30 (0.60%)
May 22 - Close
BOM real-time data - Disclaimer
Currency in INR
Range 875.00 - 893.00
52 week 655.55 - 1,224.90
Open 885.45
Vol. 17,513.00
Mkt cap 52.05B
P/E 6.02
Div/yield 2.00/0.23
EPS 147.14
Shares 58.80M
Beta     -
Inst. own     -
Jul 22, 2013
Q2 2013 Strides Arcolab Ltd Earnings Release Add to calendar
Jun 10, 2013
Strides Arcolab Ltd Annual General Meeting - 11:30AM GMT+5:30 - Add to calendar
Apr 25, 2013
Q1 2013 Strides Arcolab Ltd Earnings Release
Feb 28, 2013
Q4 2012 Strides Arcolab Ltd Earnings Conference Call
Feb 28, 2013
Q4 2012 Strides Arcolab Ltd Earnings Release
  

Key stats and ratios

Q4 (Dec '12) 2012
Net profit margin 9.57% 35.82%
Operating margin 11.86% 40.14%
EBITD margin - 25.09%
Return on average assets - 16.61%
Return on average equity - 49.81%
Employees 3,001 -
Carbon Disclosure Rating - -

Address

Strides House Bannerghatta Road, Bilekahalli
BANGALORE, 560076
India
+91-80-67840000 (Phone)
+91-80-67840700 (Fax)

Website links

External links

Discussion Group - Google Finance

Description

Strides Arcolab Limited (Strides) is a global pharmaceutical company. Strides develops and manufactures a range of intellectual property (IP)-led pharmaceutical products. It has two divisions: Specialty (Agila) and Pharmaceuticals. As of December 31, 2011, it had 14 manufacturing facilities across five locations, a research and development (R&D) hub in Bangalore, and a marketing network spanning 75 countries. On January 1, 2011, it acquired Agila Marketing e Distribuicao de Productos Hospitalares Ltda and Agila Especialidades Farmaceuticas Ltda. In April 2012, its subsidiary, Agila Specialities, acquired Sterile Formulations facility located at Hosur from Star Drugs and Research Labs. Two facilities in Bangalore, India received the United States Food & Drug Administration (FDA) approvals, during the year ended December 31, 2011. The Brazilian Sterile Penems Facility received US FDA approval, in February 2012. On January 24, 2012, it sold its investments in Ascent Pharmahealth Limited.

Officers and directors

Arun Kumar Executive Vice Chairman of the Board, Chief Executive Officer, Managing Director
T. S. Rangan Ph.D. Group Chief Financial Officer
Subroto Banerjee President - Agila, India region
Manish Gupta Chief Executive Officer - Pharma
Anand Iyer Chief Executive Officer - Agila Biotech Division
Venkat S. Iyer Chief Executive Officer - Agila
Adam Levitt Chief Executive Officer - Americas Operations
Age: 46
Sinhue B. Noronha Chief Executive Officer, Africa
Sridhar S. Rao President - Quality Assurance
D. P. Shrivastava Chief Executive Officer, Brazil